IPCALABIPCA Laboratories Limited Forensic Risk Analysis

Pharmaceuticals
Risk ClassStable
Market Cap₹38,309 Cr
Primary DriverCompetitive Position
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
16 / 100
+5 QoQ
Early Deterioration
Sentinel Insight

Financial profile remains stable for now. Weakness is detected in competitive position. No immediate concerns are visible. Risk is increasing at a faster pace.

47.5th %ile (Sector)Accel: +1 Qtrs
Updated2026-06-02
Market View
₹1,507.7▲1.16%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Competitive Position
+10.6 pts
Balance Sheet Stress
+8.8 pts
Stability Adjustment
-3.0 pts
Final Composite Risk16 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 0 → 16 over 12 quarters.

Expected Direction
⚠ Watch
Primary Deterioration Drivers
  • Relative Growth Weakness
  • Working Capital Expansion
  • Profit Collapse
What to Watch Next Quarter
  • Operating profit margins
  • Working capital efficiency

Active Risk Objects (4)

CriticalHigh
Profit Collapse
📊 Earnings QualityQuarterlyActive for 1 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ4 FY2024
IPCALAB: Net Profit collapsed by 98.3% from FY2023 Q4 to FY2024 Q4.

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Relative Growth Weakness
📊 Earnings QualityAnnualActive for 4 Years
More Detail
Impact Weight12/15
MomentumPersistent
Last SignalQ4 FY2026
Revenue growth consistently lags behind sector median (13.1%).

"Early signs of earnings quality decay. Profitability is being driven by non-core items."

Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 4 Years
More Detail
Impact Weight10/15
MomentumPersistent
Last SignalQ4 FY2026
Working capital expansion detected: Receivable days increased by -1.6%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Capex Efficiency Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight8/15
MomentumAccelerating
Last SignalQ2 FY2026
Aggressive Capex (17.9%) amidst slow revenue growth (8.5%).

"Early signs of earnings quality decay. Profitability is being driven by non-core items."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)47.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+50.0+47.0✅ RESILIENT
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹1,507.7(+1.16%)
1M Divergence-3.78%
1 Week-4.46%
1 Month-1.52%
6 Months+3.65%
1 Year+6.64%
2 Year+31.41%
3 Year+112.39%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in competitive position remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. Strategic vigilance is advised as structural decay is accelerating.

IPCALAB • MARKET STRUCTURE

Stage 2 — Advancing

The company is in a growth phase. Institutional sentiment is highly positive, supported by strong fundamentals and sustained risk reduction.

Stage Transition Prob.94%
Trend QualityDeveloping
Phase Progression
Phase Progression Score65%
Readiness LabelModerate (Transition Potential Building)
Probability of Advancing94%
CoinTree Momentum
Composite Z-Score-0.2762σ
Weakening momentum trend
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#1595 of 2716
Top 58.73% in momentum strength
Timeframe Sparklines
1W-4.5%
1M-1.5%
6M+3.6%
Weinstein Indicators
150 DMA₹1,470.5
200 DMA₹1,440.26
150 DMA Slope+2.1997%Rising
Relative Strength+9.82%Leading
Relative Turnover (RTR)1.3067
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

Risk profile is broadly in line with the Sector Mean (19).
IPCALABIPCA Laboratories Limited
16 Risk
Sector %ile47th
Delta+5
Active Flags4
Accel+1
Competitive Position

Stable

AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

AARTIPHARMAarti Pharmalabs Limited
35 Risk
Sector %ile81th
Delta0
Active Flags18
Accel+0
Earnings Quality

Watch

ALBERTDAVDAlbert David Limited
37 Risk
Sector %ile90th
Delta-8
Active Flags27
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
5.656th %ile
VS Sector Median (8.5)
Competitive Position
329.6th %ile
VS Sector Median (8.5)
Growth Sustainability
10100th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Relative Growth Weakness

2026

Working Capital Expansion

2026

Relative Growth Weakness

2026

Relative Growth Weakness

2026

Capex Efficiency Stress

2026

Relative Growth Weakness

2025

Working Capital Expansion

2024

Working Capital Expansion

2024

Working Capital Expansion

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY20269,8211,1841,142704
FY20259,0327851,3211,302
FY20247,8305239451,388
FY20236,3704798061,458